NOVATO, Calif., Nov. 30 (HSMN NewsFeed) — BioMarin Laboratory Inc. (Nasdaq: BMRN ) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the ra…
Biopharmaceuticals, FDA
BioMarin Pharmaceutical, 3,4-diaminopyridine, Lambert Eaton Myasthenic Syndrome

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “FDA Grants Orphan Drug Designation for THREE,4-DAP for LEMS”
Leave a Comment